JP2009532029A - 癌の予報および予後方法および癌治療のモニタリング - Google Patents

癌の予報および予後方法および癌治療のモニタリング Download PDF

Info

Publication number
JP2009532029A
JP2009532029A JP2009503038A JP2009503038A JP2009532029A JP 2009532029 A JP2009532029 A JP 2009532029A JP 2009503038 A JP2009503038 A JP 2009503038A JP 2009503038 A JP2009503038 A JP 2009503038A JP 2009532029 A JP2009532029 A JP 2009532029A
Authority
JP
Japan
Prior art keywords
sorafenib
amount
mmp
subject
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503038A
Other languages
English (en)
Japanese (ja)
Inventor
ウイルヘルム、スコット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of JP2009532029A publication Critical patent/JP2009532029A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
JP2009503038A 2006-03-31 2007-03-30 癌の予報および予後方法および癌治療のモニタリング Pending JP2009532029A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78769306P 2006-03-31 2006-03-31
US90168207P 2007-02-16 2007-02-16
PCT/US2007/007965 WO2007123722A2 (en) 2006-03-31 2007-03-30 Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Publications (1)

Publication Number Publication Date
JP2009532029A true JP2009532029A (ja) 2009-09-10

Family

ID=38430446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503038A Pending JP2009532029A (ja) 2006-03-31 2007-03-30 癌の予報および予後方法および癌治療のモニタリング

Country Status (4)

Country Link
EP (1) EP2002264A2 (de)
JP (1) JP2009532029A (de)
CA (1) CA2648106A1 (de)
WO (1) WO2007123722A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518837A (ja) * 2013-04-25 2016-06-30 シービーエス バイオサイエンス，カンパニー，リミテッド 肝細胞癌において分子標的治療の感受性を増加させるための分析方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
EP2324825A1 (de) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
RU2010123381A (ru) * 2007-11-09 2011-12-20 Дженентек, Инк. (Us) Способ и композиции для диагностического применения у раковых пациентов
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
WO2010022227A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Methods for monitoring il-10 therapy
EP2350663A2 (de) * 2008-10-21 2011-08-03 Bayer HealthCare LLC Identifizierung von signaturgenen in zusammenhang mit hepatozellulärem karzinom
US20190207946A1 (en) * 2016-12-20 2019-07-04 Google Inc. Conditional provision of access by interactive assistant modules
EP3682345B1 (de) 2018-08-07 2021-11-24 Google LLC Zusammenstellung und auswertung der antworten eines automatisierten assistenten für datenschutzrechtliche bedenken

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937837A2 (de) * 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Verfahren und kits zur vorhersage von therapieerfolg, nichtwiederauftreten und gesamtüberleben bei krebstherapien

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518837A (ja) * 2013-04-25 2016-06-30 シービーエス バイオサイエンス，カンパニー，リミテッド 肝細胞癌において分子標的治療の感受性を増加させるための分析方法

Also Published As

Publication number Publication date
CA2648106A1 (en) 2007-11-01
EP2002264A2 (de) 2008-12-17
WO2007123722A2 (en) 2007-11-01
WO2007123722A3 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
US8329408B2 (en) Methods for prognosis and monitoring cancer therapy
JP2009532029A (ja) 癌の予報および予後方法および癌治療のモニタリング
US20070178494A1 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20070065827A1 (en) Gene expression profiles and methods of use
EP1945819B1 (de) Genexpressionsprofile und anwendungsverfahren
EP1603514A2 (de) Expressionsprofile für dickdarmkrebs und anwendungsverfahren
JP2007507243A (ja) 遺伝子発現プロファイルおよび使用方法
US20040191819A1 (en) Expression profiles for breast cancer and methods of use
JP2007515957A (ja) ガンの予示及び予後ならびにガン治療の監視のための方法
US20040121375A1 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2006032009A2 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2005067650A2 (en) Gene expression profiles and methods of use